Research Use Only - Not for human consumption. 18+ only.

GHRP-2 vs Tesamorelin

Evidence-based comparison · Updated 2026

Summary

Tesamorelin is the stronger choice for visceral fat reduction and metabolic improvement, backed by FDA approval and clinical trial data. GHRP-2 is better suited for broad GH stimulation, appetite enhancement, and recovery support in a research context. Choose Tesamorelin for targeted body composition goals with regulatory backing; choose GHRP-2 for general GH secretagogue activity where appetite stimulation is acceptable.

Side-by-Side Comparison

GHRP-2Tesamorelin
EvidenceCGrade CPrimarily animal or in-vitro studies; limited human dataAGrade ALarge human randomised controlled trials or FDA/major-authority approved
RegulatoryCompoundableCompoundableLegal to compound in the US; approved in other jurisdictions or has historical approvalFDA ApprovedFDA ApprovedApproved by the US Food and Drug Administration for at least one indication
Benefits
  • +Potent GH secretagogue
  • +Increases appetite
  • +Promotes muscle growth
  • +Enhances recovery
  • +Improves sleep quality
  • +Reduces visceral adipose tissue
  • +FDA-approved for HIV lipodystrophy
  • +Improves metabolic parameters
  • +Cognitive benefits
  • +Body composition improvement
Dosage100-300 mcg mcg — 2-3x daily2 mg mg — Daily
RouteSubcutaneousSubcutaneous
CategoryGrowth Hormone SecretagoguesGrowth Hormone Secretagogues

Full research page

GHRP-2 →

Full research page

Tesamorelin →

Which Should You Choose?

Tesamorelin acts on GHRH receptors to mimic the body's natural GH-releasing signal, producing a regulated and pulsatile GH response. GHRP-2 activates ghrelin receptors to directly stimulate somatotrophs while suppressing somatostatin, producing a stronger and less selective GH pulse with additional appetite and cortisol effects.

Choose GHRP-2 when:

  • +Research goal involves broad GH stimulation rather than targeted visceral fat reduction
  • +Appetite stimulation is a desired or acceptable outcome in the research context
  • +Budget or access constraints make compoundable peptides the more practical option

Choose Tesamorelin when:

  • +Primary objective is clinically validated reduction of visceral adipose tissue
  • +FDA-approved status and Grade A evidence are required for the research or clinical context
  • +Metabolic parameters such as insulin sensitivity and lipid profiles are key outcome measures

Stacking GHRP-2 with Tesamorelin is theoretically plausible since they act on different receptor pathways, but no clinical data supports this combination and the additive cortisol and prolactin burden from GHRP-2 may complicate the metabolic profile Tesamorelin is intended to improve.

Frequently Asked Questions

Does GHRP-2 or Tesamorelin produce a stronger GH pulse?⌄
GHRP-2 generally produces a more potent acute GH pulse because it simultaneously activates ghrelin receptors and suppresses somatostatin, removing two brakes on GH release at once. Tesamorelin stimulates GH through GHRH receptor activation alone, resulting in a more physiologically regulated pulse. For raw GH elevation, GHRP-2 has the edge; for sustained, metabolically targeted GH activity, Tesamorelin's mechanism is more precise.
How do the timelines for visible results differ between GHRP-2 and Tesamorelin?⌄
Tesamorelin's visceral fat reduction effects have been documented over 26-week clinical trials, with statistically significant changes in trunk fat typically observed by week 12 in research subjects. GHRP-2 produces acute GH elevations within minutes of administration, but measurable body composition changes in research settings are generally reported over similar multi-week periods. Tesamorelin has more defined timeline benchmarks due to its clinical trial history, whereas GHRP-2 timelines rely on less controlled research data.
Can GHRP-2 and Tesamorelin be used together, and is there a rationale for combining them?⌄
The combination targets two separate receptor systems, GHRH receptors via Tesamorelin and ghrelin receptors via GHRP-2, which in principle could produce an additive GH response similar to how GHRH and GHRP combinations are used in GH stimulation testing. However, no published clinical data validates this specific stack for safety or efficacy. The increased cortisol and prolactin elevation associated with GHRP-2 may counteract some of Tesamorelin's intended metabolic benefits, making the combination difficult to justify based on current evidence.
Which peptide is more appropriate when metabolic health markers are a primary concern?⌄
Tesamorelin has demonstrated improvements in triglyceride levels, insulin-like growth factor 1 (IGF-1), and visceral fat mass in FDA-reviewed clinical trials, making it the evidence-supported choice when metabolic parameters are the focus. GHRP-2 has not been evaluated in comparable clinical trials for metabolic endpoints, and its stimulation of cortisol could negatively influence insulin sensitivity over time. For research prioritizing metabolic outcomes, Tesamorelin's Grade A evidence base and regulatory history make it the more defensible selection.

Not sure which fits your research goals?

Use the Goal Finder

Answer 3 questions and get a personalised peptide recommendation ranked by evidence grade.

Find My Peptide →

More Comparisons

bpc 157 vs tb 500mots c vs semaglutidedsip vs melanotan iiretatrutide vs tirzepatidecjc 1295 vs ipamorelin